Daniel Rea

Publications

  1. Abstract › Research › Not peer-reviewed
  2. Published
  3. Published
  4. Abstract › Research › Peer-reviewed
  5. Published
  6. Chapter › Research
  7. Published

    Oncology Emergencies

    Daniel Rea, Stephen Bain & Janesh Gupta, 1 Jan 2006, Core Clinical Cases.

    Research output: Chapter in Book/Report/Conference proceedingChapter

  8. Paper › Research › Not peer-reviewed
  9. Published

    Dietary phytoestrogens influence susceptibility to breast cancer by inhibiting sulphotransferase enzymes?

    Chris Kirk, , , Philip Hughes, , Daniel Rea & Rosemary Waring, 1 Jan 2001, p. 82. 1 p.

    Research output: Contribution to conference (unpublished)Paper

  10. Article › Research › Not peer-reviewed
  11. Published
  12. Published

    A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first line therapy for advanced colorectal cancer

    Daniel Rea, , , , , , , , , Neil Steven, , & , 25 May 2005, In: Annals of Oncology. 16, 7, p. 1123-1132 10 p.

    Research output: Contribution to journalArticle

  13. Published
  14. Published

    Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer

    Daniel Rea, 1 Jan 2004, In: Therapy. 1, p. 1-14 14 p.

    Research output: Contribution to journalArticle

  15. Published

    Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

    Daniel Rea, , , , , , , , , , , , , , & , 1 Jan 2011, In: Lancet. 377, 9762, p. 321-331 11 p.

    Research output: Contribution to journalArticle

  16. Published

    Antibacterial prophylaxis after chemotherapy for solid tumours and lymphomas

    Neil Steven, Lucinda Billingham, , , , , Daniel Rea, , , & , 8 Sep 2005, In: New England Journal of Medicine. 353, 10, p. 988-998 11 p.

    Research output: Contribution to journalArticle

  17. Published
  18. Published
  19. Published

    Chemotherapy for advanced colorectal cancer

    Daniel Rea, 1 Jan 2003, In: Colonews. 1, p. 3-6 4 p.

    Research output: Contribution to journalArticle

  20. Published

    Coagulopathic complications in breast cancer

    Paul Stonelake, Daniel Rea & Gregory Lip, 15 Oct 2003, In: Cancer. 98, p. 1578-1586 9 p.

    Research output: Contribution to journalArticle

  21. Published
  22. Published

    Endocrine therapy for early breast cancer

    Syed Hussain, , & Daniel Rea, 1 Oct 2004, In: Expert Review of Anticancer Therapy. 4, p. 877-888 12 p.

    Research output: Contribution to journalArticle

  23. Published
  24. Published
  25. Published
  26. Published
  27. Published

    Genomics and pharmacogenomics in the management of breast cancer

    Jennifer Pascoe, Daniel Palmer, , Daniel Rea & Syed Hussain, 1 Mar 2009, In: Current Pharmacogenomics. 6, 1, p. 45-55 11 p.

    Research output: Contribution to journalArticle

  28. Published
  29. Published
  30. Published

    Metastatic breast cancer response after exemestane withdrawal: A case report

    Daniel Rea, 1 Jan 2004, In: The Breast. 13, p. 66-68 3 p.

    Research output: Contribution to journalArticle

  31. Published

    Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

    Daniel Rea, , , , , , , , , , , , & , 6 Oct 2003, In: British Journal of Cancer. 89, 7, p. 1155-1158 4 p.

    Research output: Contribution to journalArticle

  32. Published

    Molecularly targeted therapeutics for breast cancer

    Syed Hussain, Daniel Palmer, & Daniel Rea, 1 Jan 2007, In: BioDrugs. 21, 4, p. 215-224 10 p.

    Research output: Contribution to journalArticle

  33. Published
  34. Published

    Monitoring the introduction of new drugs: Herceptin and cardiotoxicity

    Daniel Rea & , 1 Jan 2006, In: Clinical Medicine. 6, p. 478-481 4 p.

    Research output: Contribution to journalArticle

  35. Published

    Perspectives on the future of bisphosphonate use in breast cancer patients

    Daniel Rea, 1 Jan 2004, In: Seminars in Oncology. 31, p. 87-91 5 p.

    Research output: Contribution to journalArticle

  36. Published
  37. Published
  38. Published
  39. Published

    Recent advances in chemotherapy for colorectal cancer

    Daniel Rea & David Kerr, 1 Jan 2002, In: Cancer Topics. 10, p. 16-19 4 p.

    Research output: Contribution to journalArticle

  40. Published
  41. Published

    Role of Tyrosine Kinase Inhibitors in Lung Cancer

    Daniel Palmer, Daniel Rea & Syed Hussain, 1 Jun 2009, In: Anti-Cancer Agents in Medicinal Chemistry. 9, 5, p. 569-575 7 p.

    Research output: Contribution to journalArticle

  42. Published

    Role of chemotherapy in breast cancer

    Syed Hussain, Daniel Palmer, , , Christopher Poole & Daniel Rea, 1 Jan 2005, In: Expert Review of Anticancer Therapy. 5, p. 1095-1110 16 p.

    Research output: Contribution to journalArticle

  43. Published
  44. Published
  45. Published
  46. Article › Research › Peer-reviewed
  47. Published
  48. Published
  49. Published

    Addressing overtreatment of screen detected DCIS; the LORIS trial

    Toon Brookes, Tracy Roberts, Sarah Pirrie, Lucinda Billingham & 2 others, Sarah Bowden & Daniel Rea, Nov 2015, In: European Journal of Cancer. 51, 16, p. 2296-2303 8 p.

    Research output: Contribution to journalArticlepeer-review

  50. Published
  51. Published

    Adjuvant tamoxifen: How long before we know how long?

    Daniel Rea, Christopher Poole & Richard Gray, 16 May 1998, In: BMJ. 316, 7143, 1 p.

    Research output: Contribution to journalArticlepeer-review

  52. E-pub ahead of print

    Adjuvant tamoxifen and exemestane in postmenopausal early breast cancer: ten-year analysis of the randomised phase III TEAM trial

    Daniel Rea, , , , , & , 18 Jul 2017, (E-pub ahead of print) In: The Lancet Oncology.

    Research output: Contribution to journalArticlepeer-review

  53. Published
  54. Published

    Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials

    Richard Gray & , 3 Oct 2015, In: The Lancet. 386, 10001, p. 1341-1352 12 p.

    Research output: Contribution to journalArticlepeer-review

  55. Published
  56. Published

    Cardiac safety of simultaneous anti-HER2 and anthracycline therapy

    Mariam Jafri & Daniel Rea, Feb 2016, In: Breast Cancer Management. 5, 1, p. 21-29

    Research output: Contribution to journalArticlepeer-review

  57. E-pub ahead of print

    Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

    Daniel Rea & 1 others, , 26 May 2017, (E-pub ahead of print) In: Modern Pathology. 30, p. 1069-1077

    Research output: Contribution to journalArticlepeer-review

  58. Published

    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

    Daniel Rea & 8 others, , , , , , , & , Oct 2020, In: The Lancet Oncology. 21, 10, p. 1296-1308 13 p.

    Research output: Contribution to journalArticlepeer-review

  59. E-pub ahead of print

    Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study

    Daniel Rea, Dec 2021, In: Breast Cancer. 7, 1, 13 p., 90.

    Research output: Contribution to journalArticlepeer-review

  60. Published
  61. Published

    Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013

    Daniel Rea, & , 1 Oct 2016, In: Cancer Epidemiology. 44, p. 186-194 9 p.

    Research output: Contribution to journalArticlepeer-review

  62. Published

    Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training

    3 Sep 2020, In: PLoS ONE. 15, 9 September, e0238593.

    Research output: Contribution to journalArticlepeer-review

  63. Published
  64. Published

    Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

    Daniel Rea, 29 Oct 2013, In: British Journal of Cancer. 109, 9, p. 2453-2461 9 p.

    Research output: Contribution to journalArticlepeer-review

  65. Published
  66. E-pub ahead of print

    Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

    & 2 others, Daniel Rea & , Dec 2021, In: Breast Cancer. 7, 1, 8 p., 74.

    Research output: Contribution to journalArticlepeer-review

  67. Published
  68. Published

    Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis

    Daniel Rea, , , , , , , & , 1 Feb 2013, In: Oncologist. 18, 1, p. 8-13 6 p.

    Research output: Contribution to journalArticlepeer-review

  69. E-pub ahead of print
  70. Published
  71. Published
  72. Published

    Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial

    Daniel Rea, , , , , & , 1 Aug 2018, In: European Journal of Cancer . 99, p. 1-8 8 p.

    Research output: Contribution to journalArticlepeer-review

  73. Published
  74. Published
  75. Published
  76. Published

    Low grade Ductal Carcinoma in situ (DCIS): how best to describe it?

    Daniel Rea, 1 Oct 2014, In: The Breast. 23, 5, p. 693-696 4 p.

    Research output: Contribution to journalArticlepeer-review

  77. Published
  78. Published

    Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

    Toon Brookes, , , , , , , Daniel Rea, & , 2017, In: Breast Cancer. 3, p. 3

    Research output: Contribution to journalArticlepeer-review

  79. Published

    Multicentre prospective observational study evaluating recommendations for mastectomy by multidisciplinary teams

    Daniel Rea, Feb 2020, In: British Journal of Surgery. 107, 3, p. 227-237 11 p.

    Research output: Contribution to journalArticlepeer-review

  80. Published

    Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study

    Daniel Rea & , 20 Sep 2014, In: Journal of Clinical Oncology. 32, 27, p. 2951-2958

    Research output: Contribution to journalArticlepeer-review

  81. Published

    Neoadjuvant chemotherapy in triple negative breast cancer: An observational study

    Daniel Rea, 2 May 2016, In: Oncology Research. 23, 6, p. 291-302 12 p.

    Research output: Contribution to journalArticlepeer-review

  82. Published
  83. E-pub ahead of print
  84. E-pub ahead of print

    Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

    Daniel Rea, , , , , , , , , , , , & , 25 Jul 2020, (E-pub ahead of print) In: Clinical Oncology.

    Research output: Contribution to journalArticlepeer-review

  85. E-pub ahead of print

    Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials

    Daniel Rea, , , , , , , , & , 24 Jul 2020, (E-pub ahead of print) In: Journal of Clinical Oncology . p. JCO1902427

    Research output: Contribution to journalArticlepeer-review

  86. Published

    Pathway-based subnetworks enable cross-disease biomarker discovery

    Daniel Rea & 5 others, , , , & , 12 Nov 2018, In: Nature Communications. 9, 1, 4746.

    Research output: Contribution to journalArticlepeer-review

  87. Published
  88. Published
  89. Published

    Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

    Daniel Rea, , , , , , , , , , , , , , & , 1 Jun 2009, In: International Journal of Oncology. 34, 6, p. 1629-36 8 p.

    Research output: Contribution to journalArticlepeer-review

  90. Published

    Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

    Daniel Rea, , & , 20 May 2015, In: Journal of Clinical Oncology. 33, 15, p. 1680-1687 8 p.

    Research output: Contribution to journalArticlepeer-review

  91. Published
  92. E-pub ahead of print
  93. Published

    Reply to K.I. Pritchard

    Daniel Rea, & , 10 Dec 2013, In: Journal of Clinical Oncology. 31, 35, p. 4477-4479 3 p.

    Research output: Contribution to journalArticlepeer-review

  94. Published
  95. Published

    Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial

    Daniel Rea & 2 others, & , 1 Feb 2013, In: Clinical Oncology. 25, 2, p. 109-116 8 p.

    Research output: Contribution to journalArticlepeer-review

  96. Published
  97. Published
  98. Published

    Strategies to improve recruitment to a de-escalation trial: a mixed-methods study of the OPTIMA prelim trial in early Breast Cancer

    Jun 2020, In: Clinical Oncology. 32, 6, p. 382-389 8 p.

    Research output: Contribution to journalArticlepeer-review

  99. Published
  100. Published
  101. Published

    The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer: When might multigene assays be of value?

    Daniel Rea, , , , , , , , , , , , , & , 1 Jun 2017, In: The Breast. 33, p. 191-199 9 p.

    Research output: Contribution to journalArticlepeer-review

  102. Published

    The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

    & 35 others, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & Daniel Rea, 1 Feb 2019, In: Journal of Clinical Epidemiology. 106, p. 108-120 13 p.

    Research output: Contribution to journalArticlepeer-review

  103. Published

    The effect of metformin vs placebo on sex hormones in Canadian cancer trials group MA.32

    Daniel Rea & 5 others, , , , & , Feb 2021, In: Journal of the National Cancer Institute. 113, 2, p. 192-198 7 p.

    Research output: Contribution to journalArticlepeer-review

  104. Published
  105. Published

    Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer

    Toon Brookes, Daniel Rea, , , , , & , 9 Dec 2014, In: British Journal of Cancer. 111, 12, p. 2242-2247 6 p.

    Research output: Contribution to journalArticlepeer-review

  106. Published

    Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

    Aug 2021, In: The Lancet Oncology. 22, 8, p. 1139-1150 12 p.

    Research output: Contribution to journalArticlepeer-review

Previous 1 2 Next